N@N

Atrium Innovations updates its development strategy for the Wobenzym(R) brand in Germany

  //health-fitness.news-articles.net/content/2009/ .. trategy-for-the-wobenzym-r-brand-in-germany.html
  Published in Health and Fitness on Thursday, September 3rd 2009 at 4:04 GMT by Market Wire

 QUEBEC CITY, Sept. 3 /CNW Telbec/ - Atrium Innovations Inc. (TSX: ATB), a leading developer, manufacturer and marketer of science-based and professionally supported products for the Health and Nutrition industry, today announced various initiatives to support the development of its Wobenzym(R) brand in Germany. Atrium announces that Mucos Pharma, a subsidiary of Atrium, has initiated the phase out of Wobenzym(R) N in Germany earlier than initially anticipated. Concurrently, Mucos Pharma is launching a new marketing campaign for Wobenzym(R) P, a natural enzyme-based product with an active OTC drug registration. Wobenzym(R) P will be commercialized like its predecessor, Wobenzym(R) N, as systemic enzyme therapy. As planned, Mucos Pharma intends to launch a new formulation of Wobenzym(R) to be sold as a food supplement in Germany and other Western European countries in early 2010. Conference call Atrium will hold a conference call about its Wobenzym(R) commercialization strategy in Germany on September 3, 2009 at 8:45 a.m. Eastern time. Participants may access the call by using the following numbers: 1-888-231-8191 or 1-647-427-7450 (international and local calls), conference number: 28576925. A replay of the call will also be available on Atrium's website for a period of 30 days. About Atrium Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based and professionally supported products for the Health & Nutrition industry. The Company focuses primarily on growing segments of the health and nutrition markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of finished products through its highly specialized sales and marketing network in more than 35 countries, primarily in North America and Europe. Atrium has over 800 employees and operates seven manufacturing facilities. Additional information about Atrium is available on its website at[ www.atrium-innovations.com ]. Cautionary Note and Forward-Looking Statements This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law. 

For further information: Investor Relations: Mario Paradis, Vice President and Chief Financial Officer, (418) 652-1116, [ mp@atrium-innovations.com ]; Media Relations: Frédéric Tremblay, (514) 844-6665, ext. 231